Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2011-01-01
|
| Series: | Revista Brasileira de Hematologia e Hemoterapia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012 |
| _version_ | 1819070793717383168 |
|---|---|
| author | Monika Conchon Carla Maria Boquimpani de Moura Freitas Maria Aparecida do Carmo Rego José Wilson Ramos Braga Junior |
| author_facet | Monika Conchon Carla Maria Boquimpani de Moura Freitas Maria Aparecida do Carmo Rego José Wilson Ramos Braga Junior |
| author_sort | Monika Conchon |
| collection | DOAJ |
| description | Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects. |
| first_indexed | 2024-12-21T17:11:35Z |
| format | Article |
| id | doaj.art-eda7fbfea83b4b65aa90b1fa6bb7c841 |
| institution | Directory Open Access Journal |
| issn | 1516-8484 1806-0870 |
| language | English |
| last_indexed | 2024-12-21T17:11:35Z |
| publishDate | 2011-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Revista Brasileira de Hematologia e Hemoterapia |
| spelling | doaj.art-eda7fbfea83b4b65aa90b1fa6bb7c8412022-12-21T18:56:23ZengElsevierRevista Brasileira de Hematologia e Hemoterapia1516-84841806-08702011-01-0133213113910.5581/1516-8484.20110034Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaMonika ConchonCarla Maria Boquimpani de Moura FreitasMaria Aparecida do Carmo RegoJosé Wilson Ramos Braga JuniorDasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012Leukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug toxicityDrug interactionsGastrointestinal tractDrug resistance, neoplasmPyrimidinesInterferonalphaPiperazinesClinical Trial |
| spellingShingle | Monika Conchon Carla Maria Boquimpani de Moura Freitas Maria Aparecida do Carmo Rego José Wilson Ramos Braga Junior Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia Revista Brasileira de Hematologia e Hemoterapia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Drug toxicity Drug interactions Gastrointestinal tract Drug resistance, neoplasm Pyrimidines Interferonalpha Piperazines Clinical Trial |
| title | Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| title_full | Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| title_fullStr | Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| title_full_unstemmed | Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| title_short | Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia |
| title_sort | dasatinib clinical trials and management of adverse events in imatinib resistant intolerant chronic myeloid leukemia |
| topic | Leukemia, Myelogenous, Chronic, BCR-ABL Positive Drug toxicity Drug interactions Gastrointestinal tract Drug resistance, neoplasm Pyrimidines Interferonalpha Piperazines Clinical Trial |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842011000200012 |
| work_keys_str_mv | AT monikaconchon dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia AT carlamariaboquimpanidemourafreitas dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia AT mariaaparecidadocarmorego dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia AT josewilsonramosbragajunior dasatinibclinicaltrialsandmanagementofadverseeventsinimatinibresistantintolerantchronicmyeloidleukemia |